Interaction of sulfonylureas with pancreatic β-cells: a study with glyburide

• Published in: Diabetes (New York, N.Y.) Vol. 37; no. 8; pp. 1090 - 1095
• Main Authors: GORUS, F. K, SCHUIT, F. C, IN'T VELD, P. A, GEPTS, W, PIPELEERS, D. G
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.08.1988
• Subjects: Animals; Biological and medical sciences; Cyclic AMP - metabolism; Glucagon - pharmacology; Glucose - metabolism; Glucose - pharmacology; Glyburide - metabolism; Glyburide - pharmacology; Hormones. Endocrine system; Insulin - metabolism; Insulin Secretion; Islets of Langerhans - drug effects; Islets of Langerhans - metabolism; Male; Medical sciences; Oxidation-Reduction; Pharmacology. Drug treatments; Rats; Rats, Inbred Strains; Tolbutamide - pharmacology; Endocrinopathy; Rat; Diabetes mellitus; Rodentia; Langerhans islet; Vertebrata; Chemotherapy; Hypoglycemic agent; Mammalia; Treatment; B-Cell; Sulfonylureas; Mechanism of action; Pancreas
• DOI: 10.2337/diab.37.8.1090
• ISSN: 0012-1797

In this study on purified rat pancreatic beta-cells, we show that the second-generation sulfonylurea glyburide stimulates insulin release through a direct interaction with the beta-cells. During static incubations, 2 microM glyburide releases 0.16 pg insulin per beta-cell, which corresponds to a half-maximal glucose stimulation. This effect occurs independently from the glucose-recognition unit, being detectable at both nonstimulatory and stimulatory glucose concentrations and proceeding without alterations in the rate of glucose oxidation. The secretagogue action of glyburide appears not to be mediated through cAMP but is potentiated by cAMP-generating substances such as glucagon (10(-8) M; 0.31 pg insulin released per beta-cell). Its 10-fold higher potency in isolated islets is attributed to the markedly higher cAMP levels that are maintained in islet beta-cells under the influence of locally released glucagon. Perifused pancreatic beta-cells respond to glyburide with a biphasic insulin release. After removal of the drug, the cells continue to secrete insulin at the same rate for greater than or equal to 30 min. This prolonged secretory activity coincides with a cellular accumulation of the drug, primarily in association with membranes of secretory vesicles and mitochondria. Tolbutamide also stimulates insulin release from pure beta-cells, but it is less powerful on a molar basis and does not lead to a sustained hormone release after its removal from the extracellular medium. We conclude that the hypoglycemic action of glyburide is at least partly the result of a direct interaction with pancreatic beta-cells.